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INTRODUCTION 
In June 2013, the Supreme Court of the United States decided the 
Association for Molecular Pathology v. Myriad Genetics case.1  That decision 
will change the future of patent eligible subject matter.  The decision was one 
of the first cases the Supreme Court determined after the adoption of the 
America Invents Act of 2013 (“AIA”).2   Specifically, the Myriad decision deals 
with 35 U.S.C. §101 and patent eligible subject matter related to gene patents.3  
The circuit court initially held that both isolated DNA and synthetically created 
complimentary DNA (cDNA) were patent eligible subject matter under section 
 
1.  Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
2.  Leahy-Smith America Invents Act, H.R. 1249, 112th Cong. (2011-12).  
3.  Myriad Genetics, Inc., 133 S. Ct. 2107. 
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101 of the AIA.4  The Supreme Court reversed in part finding that isolated 
DNA, comprised of naturally occurring segments of DNA, is not patent eligible 
subject matter.5  However, the Supreme Court found that synthetically created 
cDNA was not naturally occurring because cDNA has been stripped of its non-
coding intron component and contains only the coding exon portion of the 
DNA.6  Therefore, cDNA does not occur in nature and falls within the scope of 
patent eligible subject matter.7  There have been several district court cases8 
and two circuit court cases9 that have analyzed subject matter eligibility in light 
of the Myriad decision. 
This Comment is divided into two sections.  The first section interprets and 
analyzes how district courts and circuit courts determine patentable subject 
matter under the guidance of the Myriad decision.  The second section of the 
Comment approaches the issue from the perspective of a law student with a 
background in molecular and cellular biology.  The second section attempts to 
understand and predict the future of patentable subject matter eligibility in light 
of the Myriad Supreme Court decision and its progeny. 
I. MYRIAD AND PATENTABLE SUBJECT MATTER 
The Myriad decision is the leading authority on gene patents subject matter 
eligibility.10  The Court in Myriad addressed the issue of patenting isolated 
genes and cDNA sequences.11  Section 101 of the Patent Act12 permits patents 
to be issued to “[w]hoever invents or discovers any new and useful . . . 
composition of matter,” “but laws of nature, natural phenomena, and abstract 
ideas are basic tools of scientific and technological work that lie beyond the 
domain of patent protection.”13  The Myriad subject matter analysis relies 
heavily on the Supreme Court’s analysis in Mayo Collaborative Services.14 
 
4.  Ass’n for Molecular Pathology v. USPTO, 689 F.3d 1303, 1328 (Fed. Cir. 2012).  
5.  Myriad Genetics, Inc., 133 S. Ct. at 2119. 
6.  Id. 
7.  Id. 
8.  Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014); 
Ariosa Diagnostics, Inc, v. Sequenom, Inc., 19 F. Supp. 3d 938, 942 (N.D. Cal. 2013); In re BRCA1- 
and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d 1213 (D. Utah 2014); Genetic 
Techs. Ltd. v. Agilent Techs., 24 F. Supp. 3d 922 (N.D. Cal. 2014); Genetic Techs. Ltd. v. Lab. Corp. 
of Am. Holdings, No. 12-1736-LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014). 
9.  In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014); In re BRCA1- and BRCA2- 
Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014). 
10.  See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013). 
11.  Id. 
12.  Leahy-Smith America Invents Act, H.R. 1249, 112th Cong. (2011-12).  
13.  Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. 66 (2012). 
14.  See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013). 
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The holding in Myriad is that isolated genes do not fall within the category 
of patentable subject matter because they are naturally occurring.15  However, 
the Court  made the distinction that cDNA, which is synthetically created in a 
laboratory and is not naturally occurring, is patent eligible.16   Since the decision 
in June of 2013, several district courts have engaged in an analysis of patent 
eligible subject matter.17  Two federal circuit cases use the Myriad decision in 
the courts’ holdings.18  In order to understand where the future of gene patents 
is going, we must first look to how the cases since the Myriad decision are 
interpreted and applied, both at the district and federal level. 
A. District Courts’ Interpretation of Patentable Subject Matter 
 in Light of the Myriad Decision 
Several district court decisions have been decided since the outcome of the 
Myriad decision in June 2013, which cite to and interpret the analysis 
performed by the Supreme Court.19  The Myriad decision relies heavily on the 
analysis performed by the Supreme Court in Mayo Collaborative.20 The 
question presented by the Supreme Court in Mayo is, “do the patent claims add 
enough to their statements of the correlations to allow the processes they 
describe to qualify as patent-eligible processes that apply natural laws?”21  The 
Court in Myriad took up this analysis in its statement that isolated DNA was 
simply DNA that was isolated from a cell, which was naturally occurring and 
not patent eligible subject matter, but that cDNA was synthetically created in a 
laboratory and not occurring in nature therefore cDNA did fall within 
patentable subject matter.22 
 
 
15.  Id. 
16.  Id. 
17.  Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014); 
Ariosa Diagnostics, Inc., v. Sequenom, Inc., 19 F. Supp. 3d 938, 942 (N.D. Cal. 2013); In re BRCA1- 
and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d 1213 (D. Utah 2014); Genetic 
Techs. Ltd. v. Agilent Techs., Inc., 24 F. Supp. 3d 922 (N.D. Cal. 2014); Genetic Techs. Ltd. v. Lab. 
Corp. of Am. Holdings, No. 12-1736-LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014). 
18.  In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014).; In re BRCA1- and BRCA2- 
Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014). 
19.  Bristol-Myers Squibb Co., 72 F. Supp. 3d at 523; Ariosa Diagnostics, Inc., 19 F. Supp. 3d 
938; In re BRCA1- and BRCA2- Based Hereditary Cancer Test 3 F. Supp. 3d 1213, 1217; Agilent 
Techs., Inc., 24 F. Supp. 3d 922; Genetic Techs. Ltd. v. Lab. Corp. of Am. Holdings, No. 12-1736-
LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014). 
20.  See Myriad Genetics Inc., 133 S. Ct. 2107 (2013). 
21.  Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012). 
22.  See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013). 
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1. Arisoa Dignostics, Inc. v. Sequenom, Inc. (Northern District of California) 
The district court case Arisoa Diagnostics v. Sequenom, Inc. involves 
claims that are similar to the isolated DNA claims of the Myriad patent.23  The 
court stated that “he who discovers a hitherto unknown phenomenon of nature 
has no claim to a monopoly of it . . . [t]his is true even if the discovery . . . [is] 
considered groundbreaking, innovative, or brilliant.”24  “A process or method 
is not unpatentable simply because it contains a law of nature, a natural 
phenomenon, or an abstract idea.”25  It is well settled in case law that “to be 
patentable, a process that focuses upon the use of a natural law, a natural 
phenomenon, or an abstract idea must contain other elements or a combination 
of elements, referred to as an ‘inventive concept.’”26  In Myriad, the Court went 
even further in its analysis of what is considered naturally occurring stating that 
“[s]imply appending conventional steps, specified at a high level of generality, 
to laws of nature, natural phenomena, and abstract ideas cannot make those 
laws, phenomena, and ideas patentable.”27 “The [Ariosa] Court’s conclusion 
conforms [to] the relevant Supreme Court case law, in particular Flook and 
Myriad,” “even though Myriad involved composition claims rather than 
method claims.”28 
The fact that Myriad involves composition claims and Ariosa involves 
method claims does not change the analysis performed by the court.29  
“Although the Supreme Court [in Myriad] was not presented with method 
claims, the Court explained ‘had Myriad created an innovative method of 
manipulating genes while searching for the BRCA1 and BRCA2 genes, it could 
possibly have sought a method patent.’”30  Had Myriad sought protection for a 
method for DNA isolation of the BRCA1 and BRCA2 genes, the method would 
likely still be found to be ineligible subject matter.  The method patent for 
Myriad’s isolated DNA would be found to be ineligible subject matter because 
“the processes used by Myriad to isolate DNA were well understood by 
geneticists at the time of Myriad’s patents.”31  Had the inventors in Ariosa 
“created an innovative method of performing DNA detection while searching 
for paternally inherited cffDNA . . . those claims would be patentable.”32  
 
23.  Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938. 
24.  Id. at 948. 
25.  Mayo Collaborative Servs., 566 U.S. at 70. 
26.  Id. See also Parker v. Flook, 437 U.S. 584 (1978).  
27.  Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938. 
28.  Id. at 950. 
29.  Id. 
30.  Id. 
31.  Id.  
32.  Id. 
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However, “the claims presently before the court simply rely on processes to 
detect DNA that—as Sequenom (inventor) concedes—were conventional 
techniques by those in the field at the time of the invention.”33 
From Ariosa, it is clear that the District Court of the Northern District of 
California places emphasis on the naturally occurring element of patentable 
subject matter.34  Ariosa uses well-known Supreme Court cases in establishing 
the background for its understanding of Myriad.35  Additionally, the Ariosa 
court does not solely rely on the holding and reasoning of the Myriad decision, 
but includes the reasoning from previous Supreme Court decisions in its 
determination of what constitutes patent eligible subject matter under section 
101.36 
2. In re BRCA1-, BRCA2-Based Hereditary Cancer Test Patent Litigation 
(District Court of Utah) 
The District Court of Utah takes a similar approach to that of the Northern 
District of California in its interpretation and application of the Myriad 
decision.  The District Court of Utah, in In re BRCA1, BRCA2, again uses 
previous Supreme Court decisions along with the Myriad analysis and 
specifically looks to the Mayo decision to aid in its analysis.37  The language 
the court adopts from Mayo is “[p]atents drawn to be processes focused on 
patent ineligible subject matter may likewise be patent ineligible, unless the 
processes include an ‘inventive concept’ sufficient to ‘ensure that the patent in 
practice amount to significantly more than a patent upon the natural law 
itself.’”38  The In re BRCA1, BRCA2 court adopts much of the language from 
the Myriad decision.39  Regarding the exceptions of section 101 patentable 
subject matter, the court says, “patents granted over these basic tools create 
‘considerable danger’ and that their use would be ‘tied up,’ thereby ‘inhibit[ing] 
future innovations premised upon them.’”40   Following the guidance laid out 
in Mayo, “[t]he Supreme Court cautions that these exceptions to section 101 
should be applied with care, as ‘all inventions at some level embody, use, 
reflect, rest upon or apply laws of nature, natural phenomena, or abstract 
 
33.  Id. 
34.  Id. at 948. 
35.  See generally Mayo Collaborative Servs. v. Prometheus Labs, Inc., 566 U.S. 66 (2012); 
see also Parker v. Flook, 437 U.S. 584 (1978).  
36.  See generally Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938. 
37.  In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d 
1213, 1217 (D. Utah 2014). 
38.  Id. at 1258. 
39.  Id. 
40.  Id. 
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ideas.’”41 
The inventors in the In re BRCA1, BRCA2 case argued that because their 
primer claims are drawn to synthetic DNA, their BRCA1 and BRCA2 primers 
are patent eligible.42  The district court rejected that argument because the 
inventor’s primer claims are drawn to patent ineligible products of nature.43  
Additionally, the inventors in this case argued that because the “Court [in 
Myriad] found patent ineligible only isolated . . . genomic, extracted DNA, then 
the Court must have in blanket fashion ‘affirmed the patent eligibility of 
synthetic DNA,’ finding that ‘unlike isolated human genes, synthetic DNA is 
man-made and not a product of nature.’”44  The district court rejects this 
argument, specifically stating, “the only synthetic DNA the [Myriad] court 
expressly found patent eligible was cDNA, [and] even then, the Court held only 
that cDNA may be patent eligible under some circumstances:” 
As a result, cDNA is not a ‘product of nature’ and is patent-eligible 
under section 101, except insofar as very short series of DNA may have 
no intervening introns to remove when creating cDNA. In that situation, 
a short strand of cDNA may be indistinguishable from natural DNA.45 
The district court makes the inference in their conclusion that “if cDNA—
which is clearly synthetic—is sometimes patent ineligible, then implicit in the 
Supreme Court’s decision is not all synthetic DNA is patent eligible.”46  The 
Myriad Court focused on the fact that the cDNA’s contiguous sequence was 
altered in comparison to the sequence from which it was derived.47  The district 
court goes further to explain that “this court’s best reading of [Myriad] is that 
the Court concluded cDNA sometimes can be sufficiently different from 
naturally occurring matter as to merit patent eligibility.”48  However, non-
cDNA isolated DNA is patent ineligible insofar as “the location and order of 
the nucleotides existed in nature.”49 This district court reads the Supreme 
Court’s decision in Myriad to “harmonize” with lower court rulings in Myriad, 
that non-cDNA isolated DNA includes primers and probes.50  Finally, the 
 
41.  Id. at 1259. 
42.  Id. 
43.  Id. 
44.  Id. at 1261. 
45.  Id. at 1262. 
46.  Id. 
47.  Id. 
48.  Id. at 1263. 
49.  Id. 
50.  Id. 
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district “court interprets [Myriad] to stand for the proposition that even 
synthetic, non-cDNA, isolated DNA is patent ineligible where it reflects the 
same nucleotide sequence as the genomic DNA.”51 
The conclusion reached by the District Court of Utah in the In re BRCA1, 
BRCA2 decision is consistent with Myriad.  However, the Utah District Court 
expanded upon the language and interpretation of the Supreme Court language 
used in Myriad.  Inferring from the language, using the lower court and 
Supreme Court Myriad decisions for guidance, and following the backround of 
the Mayo Supreme Court patent case law, the District Court of Utah concluded 
that the key language of the phrase “synthetic” in the Myriad case is not 
dispositive in showing patent eligibility.52 
3. Genetic Technologies Ltd v. Bristol-Myers Squibb Company (District Court 
of Delaware) 
The District Court of Delaware made its own interpretation of Myriad in 
October 2014.53 In that case, the plaintiff, Genetic Technologies Ltd. 
(“GTG”),54 made the argument that Myriad “stands for the proposition that 
‘man-made DNA that is molecularly different from naturally occurring DNA 
is patent eligible in of itself.’”55  The District Court, however, said that the 
plaintiffs misread Myriad.56 The plaintiffs contend that amplified DNA is 
equivalent to cDNA and should fall within the category of patent eligible 
subject matter.57 
“GTG concedes that ‘like cDNA, the nucleotide sequence of amplified 
DNA is dictated by the naturally occurring DNA.’”58  However, GTG argued 
that “the process of amplification does not copy the methylation status of the 
DNA and incorporates cytosines into the final product of the naturally 
occurring 5-methylcytosines.59  The district court stated that, “[an] attempt to 
liken amplified DNA to cDNA contradicts the reasoning of Myriad and related 
Federal Circuit precedent, which focuses on what the claims recite rather than 
unclaimed chemical differences identified post-hoc during litigation.”60  The 
court goes even further to make its point, using language from the Myriad 
 
51.  Id. 
52.  Id.  
53.  Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014). 
54.  Id. 
55.  Id. at 536. 
56.  Id.  
57.  Id. 
58.  Id.  
59.  Id.  
60.  Id.   
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decision, stating that the methylation argument brought by GTG does not make 
their product patent eligible.61  The Supreme Court language stated, “‘Claims 
are simply not expressed in terms of chemical composition, nor do they rely in 
any way on the chemical changes that result from the isolation of a particular 
section of DNA,’ but rather ‘focus on the genetic information encoded in the 
BRCA1 and BRCA2 genes.’”62  The District Court distinguished this from the 
Supreme Court holding in Myriad because the “claims on cDNA presented no 
such problem because removal of the non-coding region sequence 
‘unquestionably creates something new,’ even though the coding regions are 
retained.”63  Claim 1 in this case recites a method for detecting a coding region 
allele using genomic DNA, which is then amplified.64  “[T]he nucleotide 
sequence of amplified DNA is dictated by the naturally occurring DNA.”65  
“Therefore, although amplification is carried out in a laboratory by a human, it 
is a replication of the native DNA sequence, resulting in a mirror image of the 
naturally-occurring genetic information.”66 
The District Court of Delaware chose to focus on the functionality of the 
product as compared to the actual product itself.  The methylation step while 
technically creating a “new” coding sequence does not alter the functionality of 
the coding process itself.  Essentially, the court explained that all GTG did was 
add this methyl group marker; this addition did not change the overall structure 
or function of the sequence in question.  Because the only change was a 
minimal methylation, the court did not view this as enough of an inventive step 
to cause the sequence to fall into the category of patent eligible subject matter. 
4.  Genetic Technologies Limited v. Agilent Technologies (Northern District 
of California) 
The technology involved in this case includes a method claim “for 
analyzing variations in non-coding intron sequences to detect linked coding 
region alleles and haplotypes.”67  Specifically, the claimed methods involve 
“amplifying genomic DNA with a primer pair that spans a non-coding region 
sequence” and use this primer pair to detect alleles.68  Additionally, this case 
focused on whether the defendant’s motion to dismiss will survive the clear and 
 
61.  Id. 
62.  Id. 
63.  Id.  
64.  Id.  
65.  Id. 
66.  Id.  
67.  Genetic Techs. Ltd. v. Agilent Techs., Inc., 24 F. Supp. 3d 922, 926 (N.D. Cal. 2014). 
68.  Id. 
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convincing standard.69  The court ultimately denied the defendant’s motion to 
dismiss on the grounds that Agilent did not show by clear and convincing 
evidence that the patent claims are not meaningfully limited applications of 
natural laws.70 
The court in Agilent only used the Myriad analysis twice.71  The way in 
which the court used the Myriad decision was to establish background on what 
the Supreme Court had said about DNA.72  This analysis does not shed much 
light on how the court applied the Myriad decision to the present case; instead 
it merely served to identify what introns are in the context of DNA.73  The 
second mention of the Myriad case is more applicable to this paper as it relates 
to how the court interpreted footnote seventeen of the case.74  Footnote 
seventeen states that “Agilent argues that, unlike cDNA, amplified DNA is not 
patent eligible under Myriad.  Even so, GTG does not purport to have patented 
the amplified DNA itself, but rather methods utilizing amplified DNA.”75  The 
Court in Myriad was careful to point out that its decision did not reach any 
method claims or applications of natural laws.”76 
The court, in denying the motion to dismiss, is going towards a finding that 
this case may involve subject matter that cannot be patented.  More and more, 
courts are looking into naturally occurring elements of patents.  In this case 
specifically, the court did not find clear and convincing evidence that the 
subject matter itself was not, generally speaking, naturally occurring. 
B. Federal Circuits’ Application of the Myriad Interpretation 
The Federal Circuit has heard two cases arising out of the litigation 
following the Myriad decision.77  Both of these cases will serve to help 
understand where the future of gene patents lies.  Because patents cases are 
federally regulated, the Federal Circuit cases yield more insight as to how lower 
courts are ultimately interpreting and applying the Myriad decision.  The first 
case heard in the Federal Circuit was In re Roslin Institute, decided May 8, 
 
69.  Id. at 927. 
70.  Id. at 923. 
71.  Id. at 926. 
72.  Id. 
73.  Id. 
74.  Id. at 933, n. 17. 
75.  Id. 
76.  Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119–2120 
(2013). 
77.  In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014); In re BRCA1- and BRCA2- 
Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (2014). 
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2014.78  Roslin was subsequently followed by In re BRCA1, BRCA2, which was 
decided December 17, 2014. 
1. In re Roslin Institute 
This case is about the first large mammal cloned from an adult somatic cell: 
Dolly the sheep.79   A clone is defined in this case as “an identical genetic copy 
of a cell, cell part, or organism.”80  In order to achieve this scientific 
breakthrough, the scientists performed a technique known as somatic cell 
nuclear transfer.81  The patent at issue in this case, however, is not the somatic 
cell nuclear transfer technique.82  Inventors attempted to gain a patent on the 
actual clones themselves, which was rejected by an examiner at the United 
States Patent and Trademark Office.83  The examiners rejected the claims 
because they were directed at non-statutory subject matter under section 101, 
and the examiners’ rejections were upheld by the Board of Examiners.84  The 
Federal Circuit here undertook a de novo analysis of the Board’s rejection of 
patent eligibility.85 
The first analysis of the Federal Circuit points out that even before the 
Myriad decision, the Supreme Court’s opinions in Chakrabarty and Funk Bros, 
“made clear that that naturally occurring organisms are not patentable.”86 
Roslin makes the argument that “copies (clones) are eligible for protection 
because they are ‘the product of human ingenuity’ and ‘not nature’s handiwork, 
but [their] own.’”87  The Federal Circuit compares the clones made by Roslin 
to the isolated DNA in the Myriad case.88  The Federal Circuit specifically 
stated that Roslin “‘did not create or alter any of the genetic information’ of its 
claimed clones, ‘[n]or did [Roslin] create or alter the genetic structure of [the] 
DNA’ used to make its clones.”89 
The Federal Circuit affirmed the Board’s finding that Roslin’s clones were 
unpatentable subject matter for several different reasons.90  The key underlying 
theme to the affirmation of the rejection was the fact that the clones are 
 
78.  In re Roslin Inst., 750 F.3d 1333. 
79.  Id. at 1334. 
80.  Id. at 1337. 
81.  Id.  
82.  Id. 
83.  Id. at 1338. 
84.  Id. 
85.  Id. 
86.  Id. at 1336. 
87.  Id. at 1337. 
88.  Id. 
89.  Id. 
90.  Id. 
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naturally occurring.91  The Federal Circuit stated, “the claims do not describe 
clones that have markedly different characteristics from the donor animals of 
which they are copies.”92   From this language, it is clear that the Federal Circuit 
is looking at the differences between the clones and the naturally-occurring 
sheep, concluding that there were no differences between them, and thus the 
clones did not fall within the category of patentable subject matter. 
2. In re BRCA1, BRCA2 
This case arises out of the initial Myriad Supreme Court decision.93  It 
involves patents that were not considered in the Myriad decision.94  At issue in 
this specific litigation are two types of claims, (1) composition of matter claims, 
and (2) method claims.95  The composition of matter claims involve two DNA 
primers, which are “short, synthetic, single-stranded DNA molecule[s] that 
bind . . .  specifically to . . . intended target nucleotide sequence[s].”96  The 
method claims at issue involve comparisons between wild-type BRCA 
sequences and the patient’s BRCA sequences.97  The Federal Circuit looks first 
to the composition of matter claims and then to the method claims.98 
The Supreme Court decision in Myriad guides the Federal Circuit in its 
analysis of the primer claims under section 101.99  The Federal Circuit, in its 
analysis of the primer claims, articulates that primers “are not distinguishable 
from the isolated DNA found patent-ineligible in Myriad and are not similar to 
the patent-eligible cDNA.”100  The Court goes further to explain that because 
the primers “contain the identical sequence of the BRCA sequence directly 
opposite to the strand they are designed to bind . . . they are structurally 
identical to the ends of DNA strands found in nature.”101  Additionally, the 
Court states “it makes no difference” that the primers are “synthetically 
replicated.”102  The Court again looks to the functionality when determining 
whether the primers are different from their naturally occurring counterparts.103  
 
91.  Id. at 1339. 
92.  Id. 
93.  In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 774 F.3d 755, 758 
(Fed. Cir. 2014). 
94.  Id. 
95.  See generally id. 
96.  Id.  
97.  Id. 
98.  Id. at 759.  
99.  Id. 
100. Id. at 760. 
101. Id.  
102. Id.  
103. Id. at 760–61.  
CROMER.FINAL (DO NOT DELETE) 4/10/2017  12:27 AM 
340 MARQ. INTELL. PROP. L. REV. [Vol. 20:2 
 
The Federal Circuit explains “the naturally occurring sequences at issue here 
do not perform a significantly new function.”104  The Federal Court, in regards 
to functionality, reads the Supreme Court’s decision in Myriad to mean “A 
DNA structure with a function similar to that found in nature can only be patent 
eligible as a composition of matter if it has a unique structure, different from 
anything found in nature.”105 
II. CONCLUSION 
Based on the District Court’s and Federal Circuit’s interpretation of Myriad 
regarding patentable subject matter it is reasonable to conclude that the court 
now looks to functionality in determining whether or not something is naturally 
occurring.  In the District Court cases, this was illustrated when the court 
rejected the argument that a mere methylation created something new.  The 
argument that the methylation added a methyl group essentially creating a 
“new” molecule did not hold weight because, in the court’s mind, the 
functionality was still the same.  This move towards functionality being a part 
of the naturally occurring analysis is also starting to occur in the Federal Circuit.  
When looking at the In re Roslin and In re BRCA1 cases, it is clear that courts 
are looking on a broader scale to determine whether the thing in question is 
naturally occurring.  This will be important an important factor going forward 
in gene patentability. 
The courts are essentially making the test of whether a matter is naturally 
occurring more difficult to overcome, in the sense that just because of the fact 
that the matter is made in a lab does not automatically preclude it from being 
considered naturally occurring.  Quite the opposite, actually.  The standard for 
showing something is not naturally occurring is becoming difficult to meet, 
especially now that courts are not looking just to the structure of the molecule 
or gene, but also the functionality.  This can possibly be a dangerous road to 
travel down, because functionality is a very important part of patents.  It is my 
opinion that adding a methyl group to a molecule, while maybe not changing 
the function of the molecule, substantially changes the molecule.  This change, 
while not naturally occurring, is now seen by courts as not being enough to 
provide the molecule patent protection.  I think that this is an erroneous 
interpretation and has the potential to cause devastating outcomes in the future 
regarding the patenting of genes and genetic products. 
In conclusion, I caution the courts when applying this functionality test in 
making the determination of when something is naturally occurring.  
Functionality now plays an important part in the patent system, and creating a 
 
104. Id.  
105. Id. at 761. 
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more difficult hurdle in the gene patent sector could lead to stagnant innovation 
in a field that cannot afford to be stagnant. 
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